国家科技部中国科技论文统计源期刊   中国科技核心期刊   WHO西太平洋地区医学索引(WPRIM)收录期刊   湖北优秀期刊
《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>
反流性食管炎治疗的生存质量和成本-效果分析
Quality of Life and cost-effectiveness of Different Therapy for Reflux Esophagitis
投稿时间:2005-10-25  
DOI:
中文关键词:  反流性食管炎 生存质量 成本-效果分析
英文关键词:Reflux esophagitis  Quality of life  Cost-effectivness analysis
基金项目:
刘芙成  潘涛  茅为涛
成都市第一人民医院消化内科,成都610016
摘要点击次数: 1242
全文下载次数: 105
中文摘要:
      目的:评价埃索美拉唑治疗反流性食管炎(RE)的不同方案对患者生存质量的改善,并作成本-效果分析。方法:RE患者61例随机分成2组。A组:埃索美拉唑40mg qd 8周;B组:先予埃索美拉唑40mg qd,2周再予埃索美拉唑20mg qd 6周。2组同时联用莫沙比利5mg tid,8周。结果:A组与B组的症状有效率和内镜有效率差别均无统计学意义(P〉0.05)。SF-36量表评分2组都有5个维度积分较治疗前提高。B组的成本-效果比更佳。结论:对于RE患者,先予埃索美拉唑40mg每日1次2周,再予埃索美拉唑20mg每日1次6周与莫沙比利联合可能为更经济有效的选择。
英文摘要:
      Objective:To evaluate quality of life(QOL) and cost-effectivness of different plan of esomeprazole for reflux esophagitis(RE). Method:61 RE patients were randomized to 2 groups. Group A:esomeprazole 40mg once daily for 8 weeks; Group B:esomeprazole 40mg once daily for 2 weeks and then esomeprazole 20mg once daily for 6 weeks. All patients took mosapride 5mg three times daily for 8 weeks. Result:There was no statistic difference between group A and B in symptomatic effective rate and endoscopic effective rate. The scores of BP, GH, VT, SF and MH scales had significant improvement in group A and B after treatment. Group B was more cost effective. Conclusion: Esomeprazole 40mg once daily for 2 weeks and then esomeprazole 20mg once daily for 6 weeks puls mosapride perhaps the more cost effective therapy for RE patients.
查看全文  查看/发表评论  下载PDF阅读器
关闭